160 related articles for article (PubMed ID: 38316732)
1. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study.
Wu JY; Zhang ZB; Zhou JY; Ke JP; Bai YN; Chen YF; Wu JY; Zhou SQ; Wang SJ; Zeng ZX; Li YN; Qiu FN; Li B; Yan ML
Liver Cancer; 2023 Aug; 12(3):229-237. PubMed ID: 37767067
[TBL] [Abstract][Full Text] [Related]
3. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
[TBL] [Abstract][Full Text] [Related]
4. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma.
Liu H; Gan XM; Sun JM; Yang Q; Zhang DZ; Zuo YQ; Liu FL; Li B; Tan QL; Zhang J
Int Immunopharmacol; 2024 Mar; 130():111510. PubMed ID: 38422766
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
[TBL] [Abstract][Full Text] [Related]
7. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.
Li X; Wang X; Bai T; Chen J; Lu S; Wei T; Tang Z; Zhao G; Lu H; Li L; Wu F
Dig Liver Dis; 2024 Jun; 56(6):1078-1086. PubMed ID: 38114383
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study.
Wu JY; Wu JY; Li YN; Qiu FN; Zhou SQ; Yin ZY; Chen YF; Li B; Zhou JY; Yan ML
Front Oncol; 2022; 12():985380. PubMed ID: 36212494
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Wu JY; Yin ZY; Bai YN; Chen YF; Zhou SQ; Wang SJ; Zhou JY; Li YN; Qiu FN; Li B; Yan ML
J Hepatocell Carcinoma; 2021; 8():1233-1240. PubMed ID: 34676181
[TBL] [Abstract][Full Text] [Related]
10. Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody.
Wang L; Feng JK; Lu CD; Wu JY; Zhou B; Wang K; Wei XB; Liang C; Zhou HK; Shi J; Guo WX; Lau WY; Yan ML; Cheng SQ
Oncologist; 2024 Mar; ():. PubMed ID: 38478404
[TBL] [Abstract][Full Text] [Related]
11. Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study.
Li B; Wang C; He W; Qiu J; Zheng Y; Zou R; Lin Z; Shi Y; Yuan Y; Zhang R; Zhang C; Chen M; Lau WY; Yuan Y
Int J Surg; 2024 May; 110(5):2545-2555. PubMed ID: 38329081
[TBL] [Abstract][Full Text] [Related]
12. Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.
Wu J; Wu J; Li S; Luo M; Zeng Z; Li Y; Fu Y; Li H; Liu D; Ou X; Lin Z; Wei S; Yan M
Biosci Trends; 2024 Mar; 18(1):42-48. PubMed ID: 38325823
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.
Li X; Chen J; Wang X; Bai T; Lu S; Wei T; Tang Z; Huang C; Zhang B; Liu B; Li L; Wu F
Front Oncol; 2023; 13():1110689. PubMed ID: 36793614
[TBL] [Abstract][Full Text] [Related]
15. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.
Qu WF; Ding ZB; Qu XD; Tang Z; Zhu GQ; Fu XT; Zhang ZH; Zhang X; Huang A; Tang M; Tian MX; Jiang XF; Huang R; Tao CY; Fang Y; Gao J; Wu XL; Zhou J; Fan J; Liu WR; Shi YH
BJS Open; 2022 Sep; 6(5):. PubMed ID: 36125345
[TBL] [Abstract][Full Text] [Related]
16. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
17. Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.
Luo MC; Wu JY; Wu JY; Lin ZT; Li YN; Zeng ZX; Wei SM; Yan ML
J Hepatocell Carcinoma; 2023; 10():1827-1837. PubMed ID: 37850079
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
19. Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.
Lin KY; Zhang JX; Lin ZW; Chen QJ; Luo LP; Chen JH; Wang K; Tai S; Zhang ZB; Wang SF; Li JD; Wang K; Zheng L; Zheng SM; Wu MM; Lin KC; Yang T; Zeng YY
Front Immunol; 2024; 15():1308543. PubMed ID: 38433845
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus.
Wu HX; Ding XY; Xu YW; Yu MH; Li XM; Deng N; Chen JL
World J Gastroenterol; 2024 Feb; 30(8):843-854. PubMed ID: 38516240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
